Aclaris Therapeutics Cash from Financing (TTM) Insights

Aclaris Therapeutics Inc (ACRS)

1.155 -0.02 (-1.28%) USD | NASDAQ | Apr 25, 13:37

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2015. Upgrade now.

Date	Value
December 31, 2023	26.71M
September 30, 2023	26.69M
June 30, 2023	26.77M
March 31, 2023	72.84M
December 31, 2022	72.87M
September 30, 2022	72.83M
June 30, 2022	61.27M
March 31, 2022	124.33M
December 31, 2021	225.05M
September 30, 2021	232.88M
June 30, 2021	244.17M
March 31, 2021	108.20M
December 31, 2020	18.37M
September 30, 2020	-19.47M
June 30, 2020	-19.26M
March 31, 2020	-19.28M
December 31, 2019	-30.32M

Date	Value
September 30, 2019	127.88M
June 30, 2019	127.96M
March 31, 2019	127.78M
December 31, 2018	128.26M
September 30, 2018	0.00
June 30, 2018	80.90M
March 31, 2018	100.54M
December 31, 2017	100.39M
September 30, 2017	198.73M
June 30, 2017	117.82M
March 31, 2017	117.04M
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015	96.41M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-30.32M

Minimum

Dec 2019

244.17M

Maximum

Jun 2021

77.92M

Average

72.83M

Median

Sep 2022

Cash from Financing (TTM) Benchmarks